High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label‐Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis: 2038. (October 2015) - Reau, Nancy